Mangoceuticals, Inc. - Common Stock (MGRX)

Mississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company...

Mag Mile Capital, Inc. (OTCQB: MMCP) is beginning to emerge on investor radar after a sharp move higher, with the stock climbing approximately 365% from $0.12 on February 27, 2026 to $0.44 on March 20, 2026, as the company continues to execute across a growing pipeline of commercial real estate (CRE) financing transactions .

Kartoon Studios (NYSE: TOON) is drawing renewed investor interest as momentum builds across its streaming, production, and franchise expansion strategy heading into 2026. The company, a global producer and distributor of family entertainment content, operates Kartoon Channel!—consistently ranked among the top kids’ streaming apps—and owns Mainframe Studios, one of North America’s largest animation production houses.

Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.

Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.